MYGN - ミリアド・ジェネティックス (Myriad Genetics Inc.) ミリアド・ジェネティックス

 MYGNのチャート


 MYGNの企業情報

symbol MYGN
会社名 Myriad Genetics Inc. (ミリアド・ジェネティックス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: In Vitro_In Vivo Diagnostic Substances  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 ミリアド・ジェネティクス(Myriad Genetics Inc.)は分子診断会社である。同社は形質転換的分子診断検査の発見、開発、販売に従事する。同社は、診断およびその他の2つの区分を通じて事業を行う。診断セグメントは病気を発症するリスクを評価し、薬物療法に応答する患者の可能性を特定し、最適な治療を可能にするために患者の投薬を導き、患者のリスクを評価するためのテストの共同開発を提供する。その他のセグメントは、医薬品バイオテクノロジー、医療研究業界、研究開発および患者の臨床サービスに試験製品およびサービスを提供し、金融、人材、法律および情報技術などの企業サービスも含む。その分子診断検査には、myRisk遺伝性がん、BRACAnalysis CDxおよびCOLARISが含まれる。   ミリアド・ジェネティックスは、米国のバイオ医薬品企業。P4医療に焦点を置いた医薬品と分子診断製品を扱う。主要製品は遺伝性乳がんと卵巣がんの易罹患性の遺伝子検査「BRACAnalysis」、結腸直がんと子宮がんの遺伝子検査「Colaris」、メラノ―マ遺伝子検査「Melaris」、遺伝性膵臓がん発症予測検査「PANEXIA」など。   Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
本社所在地 320 Wakara Way Salt Lake City UT 84108 USA
代表者氏名 John T. Henderson ジョン・T・ヘンダーソン
代表者役職名 Independent Chairman of the Board
電話番号 +1 801-584-3600
設立年月日 33359
市場名 NASDAQ National Market System
ipoyear 1995年
従業員数 2400人
url www.myriad.com
nasdaq_url https://www.nasdaq.com/symbol/mygn
adr_tso
EBITDA EBITDA(百万ドル) 172.90000
終値(lastsale) 43.02
時価総額(marketcap) 3050993629.08
時価総額 時価総額(百万ドル) 3264.328
売上高 売上高(百万ドル) 772.60000
企業価値(EV) 企業価値(EV)(百万ドル) 393.028
当期純利益 当期純利益(百万ドル) 96.70000
決算概要 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Myriad Genetics Inc. revenues increased less than 1% to $772.6M. Net income before extraordinary items increased from $21.8M to $99.1M. Revenues reflect Other segment increase of 8% to $53.3M also reflect Diagnostics segment decrease of less than 1% to $719.3M. Net income benefited from Other segment loss decrease of 74% to $20.7M Diagnostics segment income increase of 8% to $139.4M.

 MYGNのテクニカル分析


 MYGNのニュース

   Myriad Genetics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/09 14:39:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Myriad Genetics Q1 2021 Earnings Preview (NASDAQ:MYGN)  2020/11/08 22:35:42 Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate is -$0.3
   Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies  2020/10/27 12:23:49 OpenPR
This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%  2020/10/23 10:30:43 Zolmax News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]
   Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB)  2020/10/22 09:04:47 Dakota Financial News
Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]
   Myriad Genetics Earnings and Growth Analysis : Stock market Insights & financial analysis  2020/11/09 14:39:00 Stock Market Daily
Myriad Genetics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
   Myriad Genetics Q1 2021 Earnings Preview (NASDAQ:MYGN)  2020/11/08 22:35:42 Seeking Alpha
Myriad Genetics (NASDAQ:MYGN) is scheduled to announce Q1 earnings results on Monday, November 9th, after market close. The consensus EPS Estimate is -$0.3
   Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies  2020/10/27 12:23:49 OpenPR
This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%  2020/10/23 10:30:43 Zolmax News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]
   Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB)  2020/10/22 09:04:47 Dakota Financial News
Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]
   Liquid Biopsy Market (COVID-19 Impact Analysis) 2020 Outlook Industry Analysis, Size, Share, Growth, Trends And Forecast, Leading Players are Eurofins Scientific, QIAGEN, Myriad Genetics, Genomic Health, RainDance Technologies  2020/10/27 12:23:49 OpenPR
This Liquid Biopsy Market research report makes available state-of-the-art information about the entire market along with the holistic view of the market. This global market research report displays a complete overview of the market, including myriad of aspects such as
   Myriad Genetics (NASDAQ:MYGN) Stock Price Up 5.1%  2020/10/23 10:30:43 Zolmax News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) rose 5.1% on Wednesday . The company traded as high as $14.07 and last traded at $14.02. Approximately 635,557 shares changed hands during trading, a decline of 37% from the average daily volume of 1,013,374 shares. The stock had previously closed at $13.34. MYGN has been the topic of […]
   Financial Analysis: Myriad Genetics (NASDAQ:MYGN) & Navidea Biopharmaceuticals (NASDAQ:NAVB)  2020/10/22 09:04:47 Dakota Financial News
Myriad Genetics (NASDAQ:MYGN) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends. Profitability This table compares Myriad Genetics and Navidea Biopharmaceuticals’ net margins, return on equity and […]
   Myriad Genetics (NASDAQ:MYGN) Trading 5.1% Higher  2020/10/21 17:56:58 US Banking News
Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) traded up 5.1% during mid-day trading on Wednesday . The company traded as high as $14.07 and last traded at $14.02. 635,557 shares traded hands during trading, a decline of 37% from the average session volume of 1,013,374 shares. The stock had previously closed at $13.34. A number of […]
   Myriad Genetics (NASDAQ:MYGN) Cut to Sell at BidaskClub  2020/10/20 03:52:41 Stock Observer
BidaskClub lowered shares of Myriad Genetics (NASDAQ:MYGN) from a hold rating to a sell rating in a research note released on Friday morning, BidAskClub reports. Several other equities research analysts have also weighed in on MYGN. Needham & Company LLC reaffirmed a hold rating on shares of Myriad Genetics in a report on Friday, August […]

 関連キーワード  (先端医療機器_テクノロジ― 米国株 ミリアド・ジェネティックス MYGN Myriad Genetics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)